Wall Street brokerages expect that Avrobio Inc (NASDAQ:AVRO) will report earnings per share of ($0.59) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avrobio’s earnings, with estimates ranging from ($0.70) to ($0.54). Avrobio reported earnings per share of ($0.49) in the same quarter last year, which would suggest a negative year over year growth rate of 20.4%. The company is expected to report its next earnings report on Tuesday, November 12th.

On average, analysts expect that Avrobio will report full-year earnings of ($2.52) per share for the current financial year, with EPS estimates ranging from ($2.81) to ($2.15). For the next year, analysts anticipate that the company will post earnings of ($2.68) per share, with EPS estimates ranging from ($2.94) to ($2.16). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Avrobio.

Avrobio (NASDAQ:AVRO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.09.

AVRO has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Avrobio in a report on Friday, August 9th. Zacks Investment Research downgraded shares of Avrobio from a “buy” rating to a “hold” rating in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $43.00 price target on shares of Avrobio in a report on Friday, August 9th. Cowen reissued a “buy” rating on shares of Avrobio in a report on Monday, July 15th. Finally, ValuEngine raised shares of Avrobio from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.90.

In related news, Director Bruce Booth bought 810,811 shares of the company’s stock in a transaction on Friday, July 19th. The stock was bought at an average cost of $18.50 per share, with a total value of $15,000,003.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in AVRO. Price T Rowe Associates Inc. MD grew its stake in shares of Avrobio by 33.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 808,235 shares of the company’s stock valued at $13,142,000 after acquiring an additional 203,484 shares in the last quarter. Morgan Stanley grew its stake in shares of Avrobio by 47.8% in the second quarter. Morgan Stanley now owns 55,777 shares of the company’s stock valued at $907,000 after acquiring an additional 18,038 shares in the last quarter. Invesco Ltd. grew its stake in shares of Avrobio by 3.8% in the second quarter. Invesco Ltd. now owns 148,617 shares of the company’s stock valued at $2,416,000 after acquiring an additional 5,506 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Avrobio by 12.7% in the second quarter. Vanguard Group Inc. now owns 616,917 shares of the company’s stock valued at $10,031,000 after acquiring an additional 69,383 shares in the last quarter. Finally, Farallon Capital Management LLC grew its stake in shares of Avrobio by 15.1% in the second quarter. Farallon Capital Management LLC now owns 1,036,147 shares of the company’s stock valued at $16,848,000 after acquiring an additional 136,147 shares in the last quarter. 68.55% of the stock is owned by institutional investors.

AVRO stock traded up $0.15 during trading on Friday, hitting $14.02. 160,100 shares of the stock traded hands, compared to its average volume of 234,963. Avrobio has a one year low of $11.85 and a one year high of $33.38. The stock has a market cap of $336.89 million, a price-to-earnings ratio of -3.87 and a beta of 2.63. The company has a 50 day simple moving average of $17.15 and a 200 day simple moving average of $18.09.

About Avrobio

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Featured Article: What is the price-to-earnings growth (PEG) ratio?

Get a free copy of the Zacks research report on Avrobio (AVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.